Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aimmune Therapeutics, Inc. (NASDAQ: AIMT).

Full DD Report for AIMT

You must become a subscriber to view this report.


Recent News from (NASDAQ: AIMT)

Intrommune advancing peanut allergy candidate, pre-IND meeting with FDA completed
Privately held Intromune Therapeutics met recently with the FDA to discuss the details of an IND for INT301, an immunotherapy to treat peanut allergy. Once approved, clinical studies may begin. More news on: AnaptysBio, Aimmune Therapeutics, DBV Technologies, Healthcare stocks news, ...
Source: SeekingAlpha
Date: September, 06 2018 11:15
Aimmune Therapeutics to Present at Three Investor Conferences in September
Wells Fargo Healthcare Conference, September 5 Baird Global Healthcare Conference, September 6 Bank of America Merrill Lynch Global Healthcare Conference, September 12 Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life...
Source: Business Wire
Date: August, 29 2018 08:00
Report: Developing Opportunities within Aimmune Therapeutics, Everbridge, Roku, Bristow Group, Atlas Air Worldwide, and Edgewell Personal Care - Future Expectations, Projections Moving into 2018
NEW YORK, Aug. 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aimmune Therapeutics, Inc. (NASDAQ:AIMT), Everbridge, Inc. (NASDAQ:EVBG),...
Source: GlobeNewswire
Date: August, 23 2018 08:00
Here, Take Another Hit Of This, Then Sell Some More Aimmune
Once again investors have smoked the strong stuff and sold Aimmune Therapeutics (AIMT) to levels that underprice its true value and potential. More patient - read thoughtful - investors should find these valuations compelling and an excellent entry point. Aimmune has fallen significantly below...
Source: SeekingAlpha
Date: August, 13 2018 21:03
Aimmune And DBV Technologies: A Comparison
Last year, I was quietly rooting for DBV technologies ( DBVT ) mainly because they are an European company relatively less known in the US, thus offering a solid diversification avenue. However, trial results have shown that Aimmune ( AIMT ) is probably the better drug, and although the news i...
Source: SeekingAlpha
Date: August, 13 2018 03:59
Aimmune Therapeutics misses by $0.05
Aimmune Therapeutics (NASDAQ: AIMT ): Q2 EPS of -$0.91 misses by $0.05 . More news on: Aimmune Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 08 2018 16:13
Aimmune Therapeutics Announces Second Quarter 2018 Financial Results
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2018. As of June 30, 2018, cash, cash equivalents and investments totaled $295.9 m...
Source: Business Wire
Date: August, 08 2018 16:01
Aimmune Therapeutics Announces CEO Jayson Dallas Will Present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas, M.D., will give his first public presentation as the company’s President and CEO at the 2018 Wedbush PacGrow Healthcare...
Source: Business Wire
Date: August, 07 2018 08:00
3 Solid Mid-Cap Biotechs To Close Out 2018
Ah, Winter will be here before we know it. Below are three mid-cap biotechnology stocks I believe have great risk/reward ratios and significant remaining upside before the dead of Winter hits (January). All of the mid-cap picks I present: have high cash/low debt are technical momentu...
Source: SeekingAlpha
Date: July, 22 2018 08:38
Aimmune: Societal Benefits
Anybody with kids know that peanut allergies are not only life-threatening to people with the immune deficiency but also a societal impact causing all parents to watch what food they send to school. Aimmune Therapeutics ( AIMT ) offers a possible solution that might help solve food allergies...
Source: SeekingAlpha
Date: July, 19 2018 18:47

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0826.4526.2626.5825.76214,824
2018-05-1730.0030.0130.6029.86308,254
2017-06-2017.6318.5618.9717.13453,436
2017-06-1916.5017.6917.7816.25724,653
2017-06-1617.7716.4717.8916.44760,422

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1055,58196,02957.8794Short
2018-12-0793,610141,24566.2749Short
2018-12-06111,957307,81436.3716Short
2018-12-04123,539268,99145.9268Short
2018-12-0367,507187,00736.0986Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AIMT.


About Aimmune Therapeutics, Inc. (NASDAQ: AIMT)

Logo for Aimmune Therapeutics, Inc. (NASDAQ: AIMT)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $1,552,981,463 - 05/14/2018
  • Issue and Outstanding: 51,525,596 - 02/15/2018

 


Recent Filings from (NASDAQ: AIMT)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 11 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 11 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 27 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: March, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: March, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 26 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 22 2018

 

 


Daily Technical Chart for (NASDAQ: AIMT)

Daily Technical Chart for (NASDAQ: AIMT)


Stay tuned for daily updates and more on (NASDAQ: AIMT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AIMT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AIMT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AIMT and does not buy, sell, or trade any shares of AIMT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/